Laser flare photometry: a cost-effective method for early detection of endophthalmitis after intravitreal injection of anti-VEGF agents by Lages, V. et al.
ORIGINAL RESEARCH Open Access
Laser flare photometry: a cost-effective
method for early detection of
endophthalmitis after intravitreal injection
of anti-VEGF agents
Vânia Lages1,2, Béatrice Gehrig1 and Carl P. Herbort Jr.1,3*
Abstract
Background: Intravitreal injection of anti-vascular endothelial growth factor agents is the most common intraocular
procedure worldwide, inevitably causing more cases of post-injection endophthalmitis. The purpose of this study was
to evaluate the utility of laser flare photometry in monitoring inflammation after intravitreal injection of anti-vascular
endothelial growth factor agents, particularly to detect early stage post-injection endophthalmitis.
Main body of the abstract: A retrospective case review was performed of all patients who underwent flare
assessment by laser flare photometry before and after intravitreal injection of bevacizumab or aflibercept at the
Centre for Ophthalmic Specialized Care in Lausanne, Switzerland, between January 2015 and May 2018. The
following data were retrieved: indication for intravitreal injection, medication administered, pre-injection and
72-h post-injection laser flare photometry values, and occurrence of post-injection endophthalmitis. A total of
736 injections were included in this study; 705 cases (95.8%) had a post-injection flare at 72 h ≤ 30 ph/ms, 29
cases (3.9%) had a post-injection flare at 72 h between > 30 and 50 ph/ms, and 2 cases (0.3%) had a post-injection flare
at 72 h above > 50 ph/ms (664 and 742 ph/ms). These latter two cases were diagnosed as early-stage endophthalmitis.
Conclusion: Laser flare photometry is a cost-effective method of screening for early stage post-injection endophthalmitis.
Values > 50 ph/ms 72-h post-injection should prompt immediate evaluation by an ophthalmologist.
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Background
Intravitreal injection (IVI) of anti-vascular endothelial
growth factor (VEGF) agents has revolutionized the treat-
ment of many retinal diseases, including age-related
macular degeneration, diabetic macular edema, retinal
vein occlusion, and myopic choroidal neovascularization,
and became the most common intraocular procedure
worldwide [1]. As the number of IVIs performed has in-
creased exponentially in the last 10 years, this has inevit-
ably caused more cases of post-IVI infection [2]. The most
recently reported incidence rates of endophthalmitis after
IVI of anti-VEGF agents range from 0.013 to 0.131% [3–
6]. The interval between IVI and endophthalmitis presen-
tation is approximately 3 days [2, 7]. Therefore, optimal
care means that every patient should be observed 72 h
post-IVI to achieve early diagnosis and immediate treat-
ment of post-IVI endophthalmitis. However, this scenario
is impractical for many centers due to the high volume of
patients receiving intravitreal treatment.
Several reports have been published on monitoring
pre- and post-injection flare using laser flare photometry
(LFP) [8–10]. Developed by Sawa et al. [11] in 1988, LFP
is based on the same principle as slit-lamp flare evalu-
ation, measuring back-scattered light from protein parti-
cles in the anterior chamber. The light source in LFP is
a laser beam with constant energy, and the detection of
back-scattered light (photons) is achieved in an
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automated fashion using a photomultiplier and photo-
detector, which make it a precise and objective device
for quantifying aqueous proteins [11]. LFP allows
non-invasive, objective, and quantitative measurement of
intraocular inflammation, making it possible to identify
abnormal increases in post-injection flare. The learning
curve for the technique is short and the assessment eas-
ily performed by an ophthalmic assistant.
The aims of the present study were to evaluate mean
LFP flare values pre- and post-IVI and to demonstrate
the exquisite sensitivity of LFP in detecting the early
stages of endophthalmitis, proposing the cost-effective
use of LFP to monitor post-injection flare and uncover
abnormal inflammation. The incentive to perform this
study was the detection of very early signs of endoph-
thalmitis by LFP in two cases, leading to rapid and suc-
cessful management.
Patients and methods
This was a single-center, retrospective case review per-
formed in accordance with the Declaration of Helsinki.
First, we collected the total number of IVIs administered
at the Centre for Ophthalmic Specialized Care (Lausanne,
Switzerland) in order to determine the total cases of
post-IVI endophthalmitis between January 2006 and May
2018. Second, in order to establish the mean pre- and
post-IVI LFP flare, we arbitrarily analyzed the IVIs from
January 2015 to May 2018 and reviewed the files of all pa-
tients who underwent flare assessment by LFP before and
after IVI of bevacizumab (Avastin; Roche AG, Basel,
Switzerland) and aflibercept (Eylea; Bayer AG, Basel,
Switzerland). Institutional Review Board ruled that ap-
proval was not required for the study.
The following data were retrieved: indication for
anti-VEGF IVI, anti-VEGF administered, pre-IVI (same
day or previous 7 days) and 72-h post-IVI LFP flare, and
occurrence of post-IVI endophthalmitis. Anterior cham-
ber LFP was performed using the FM-700 laser flare
meter (Kowa Co, Tokyo, Japan). Readings were obtained
by a single experienced technician (BG). Every LFP
examination included ten measurements. The two high-
est and two lowest measurements were discarded. A sin-
gle averaged reading was produced by the instrument.
IVI was performed by the same physician (CPH) in the
same operating room for all patients under sterile condi-
tions. During the procedure, the physician wore sterile
gloves, surgical mask, and cap. Sterile preservative-free
anesthetic drops with 1% tetracaine were placed in the
eye and a periocular scrub performed using 10% polyvi-
done iodine, followed by a drop of 5% polyvidone placed
on the ocular surface before the injection. A surgical
drape covering the patient’s nose and mouth and a ster-
ile lid speculum were used. An IVI of 1.25 mg in 0.05 ml
of bevacizumab or 2 mg in 0.05 ml of aflibercept was
performed 3.5 mm posterior to the limbus in pseudo-
phakic eyes and 4.0 mm posterior to the limbus in
phakic eyes. A drop of a combination of 5 mg/ml chlor-
amphenicol and 1 mg/ml dexamethasone was adminis-
tered pre and post-injection, and then prescribed three
times per day for 3 days to every patient.
Descriptive and statistical analyses were obtained using
SPSS® version 22 (SPSS Inc., Chicago, Illinois, USA). Con-
tinuous variables were presented as mean and standard
deviation (SD). Categorical variables were presented as
frequencies and percentages. The variable normal distri-
bution was tested with Kolmogorov-Smirnov and
Shapiro-Wilk tests. Wilcoxon and Mann-Whitney tests
were utilized. A p value < 0.05 was considered significant.
Results
Between January 2006 and May 2018, 2804 IVIs were
administered at COS. Two of the cases developed bac-
terial endophthalmitis during this period, which gives a
post-IVI endophthalmitis rate of 0.07%.
In order to determine the evolution of LFP flare from
pre-injection to post-injection values, a total of 736 IVIs
Table 1 Sample characterization of 736 intravitreal injections
(IVIs)
N (%)
Drug injected
Bevacizumab 113 (15.4%)
Aflibercept 623 (84.6%)
Indications for IVI
Age-related macular degeneration 469 (63.7%)
Retinal venous occlusion 193 (26.2%)
Diabetic macular edema 55 (7.5%)
Telangiectasia 5 (0.7%)
Myopic choroidal neovascular membrane 2 (0.3%)
Proliferative retinopathy due to central
arterial retinal occlusion
2 (0.3%)
Other 10 (1.4%)
Table 2 Laser flare photometry assessment
Pre-IVI flare Post-IVI flare Pb
(mean ± SD) (mean ± SD)
Global 11.5 ± 5.6 18.3 ± 36.4 < 0.001
Pa Pa
Bevacizumab IVIs 10.8 ± 4.7 0.245 14.2 ± 5.5 < 0.001 < 0.001
Aflibercept IVIs 11.7 ± 5.8 19.0 ± 39.4 < 0.001
aMann-Whitney test
bWilcoxon test
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between January 2015 and May 2018 were considered in
this study. The main indications are given in Table 1.
Pre-IVI mean LFP flare was similar between the two
drugs, but the post-IVI mean LFP flare was higher in pa-
tients injected with aflibercept than those injected with
bevacizumab (Table 2). The analysis of LFP assessment
is described in Table 2.
Figure 1 shows the distribution of 72 h post-IVI
LFP flares. A total of 705 cases (95.8%) had values ≤
30 ph/ms (range 3.3 to 29.6). Twenty-nine cases
(3.9%) had values between > 30 and 50 ph/ms (range
30.2 to 50.0). These patients were asymptomatic and
clinical examination revealed 1+ or less anterior
chamber cells. The frequency of administration of the
topical combination of antibiotic and steroid was in-
creased and more frequent follow-up visits where
scheduled. No complications were detected and LFP
flare returned to pre-injection values. Two cases
(0.3%) had values > 50 ph/ms, namely 664 and
742 ph/ms, and were diagnosed with early-stage en-
dophthalmitis (see case reports below).
Case 1
A 78-year-old female had bilateral exudative age-related
macular degeneration (AMD) diagnosed in October
2015 and was under treatment with bilateral intravitreal
anti-VEGF injections. In February 2018, the best cor-
rected visual acuity (BCVA) of her right eye had de-
creased from 0.4 to 0.2, and the optical coherence
tomography (OCT) revealed recurrence of macular ex-
udation (Fig. 2). The patient was treated with an IVI of
aflibercept. At the 72 h post-IVI control visit, the pa-
tient was symptomless. The BCVA of her right eye had
improved to 0.3 and no macular fluid was present.
However, the LFP flare had increased from 8.6 ph/ms
pre-injection to 664 ph/ms. Clinical examination re-
vealed discreet conjunctival hyperemia, clear cornea, 3+
cells in the anterior chamber, and no hypopyon. On
fundoscopy, the vitreous was slightly cloudy. Because of
the tremendously high flare and first signs of endoph-
thalmitis, the patient was immediately referred to the
retinal department with suspicion of post-IVI endoph-
thalmitis. After 2 h, before vitrectomy was performed,
the BCVA was counting fingers, biomicroscopy showed
a fine hypopyon in the anterior chamber, and the retina
could not be visualized on fundoscopy. A diagnostic vi-
trectomy was performed followed by IVI of 0.1 ml
vancomycin and 0.1 ml ceftazidime. At the same time,
systemic moxifloxacin (400 mg/day) was started with
daily parabulbar injections of betamethasone for 7 days.
Microbiological analysis identified Staphylococcus epi-
dermidis. The treatment response was satisfactory with
gradual flare regression (Fig. 3). At the last follow-up
visit 4 months later, the patient had a BCVA of 0.3, a
flare of 17.9 ph/ms, and OCT showed a dry macula
(Fig. 4).
Case 2
A 72-year-old female with bilateral, moderate, non-pro-
liferative diabetic retinopathy had a BCVA in the left
eye of 0.7 in October 2015. The OCT revealed diabetic
macular edema (Fig. 5). She was treated with an IVI of
aflibercept. At the 72-h post-injection control visit, the
BCVA was 0.5 and the LFP flare had increased from
7.0 ph/ms pre-injection to 300.4 ph/ms. The patient
was treated with a combination of 0.5% chlorampheni-
col and 0.1% dexamethasone drops every 10 min for
2 h. The LFP flare was assessed again and had further
increased to 741.9 ph/ms. Clinical examination revealed
conjunctival hyperemia, a clear cornea, 3+ cells in the
Fig. 1 Distribution of laser flare photometry values after 72 h of intravitreal injection
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anterior chamber without a hypopyon, and 3+ vitritis.
The patient was then immediately referred to the ret-
inal department with suspicion of post-IVI endophthal-
mitis. During her stay in the emergency room, a
hypopyon formed. A diagnostic vitrectomy was per-
formed with IVI of 0.1 ml vancomycin and 0.1 ml
ceftazidime. At the same time, systemic moxifloxacin
(400 mg/day) was started, as well as daily injections of
parabulbar betamethasone during the subsequent
6 days. Microbiological analysis of the vitreous
identified Staphylococcus epidermidis. The patient
responded well to the treatment with gradual flare re-
gression (Fig. 6). At the final follow-up visit, she had a
Fig. 3 Patient 1. Laser flare photometry values evolution from pre-injection level until last follow-up
Fig. 2 Patient 1. a Color retinography showing drusen and b OCT
showing fibrovascular pigment epithelium detachment with
subretinal and intraretinal fluid
Fig. 4 Patient 1. a Color retinography showing drusen and b OCT
showing fibrovascular pigment epithelium detachment with
resolution of subretinal and intraretinal fluid
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BCVA of 0.6, a flare of 9.1 ph/ms, and no significant
macular edema (Fig. 7).
Conclusions
This study is the largest retrospective study to evaluate
the utility of LFP in monitoring inflammation after intra-
vitreal anti-VEGF injection [9, 10, 12], particularly to de-
tect early-stage post-injection endophthalmitis. LFP is
routinely used in our center to evaluate intraocular in-
flammation in uveitis patients and in patients undergo-
ing intraocular procedures, namely before and after IVIs.
The two cases of bacterial endophthalmitis after 2804
injections (0.07%) at our center is in line with recent re-
ports [3–6]. We determined the evolution of LFP flare
values from pre-injection to 72 h post-injection for a
total of 736 IVIs, including the 2 cases of endophthalmi-
tis. Overall, we found that the mean LFP flare was sig-
nificantly higher 72 h post-IVI than pre-IVI for patients
injected with bevacizumab and aflibercept. This con-
trasts with previous reports [8, 9], in which no signifi-
cant difference was found between mean pre and
post-IVI LFP flare values after bevacizumab and ranibi-
zumab injections, but the difference can be justified by
our larger sample. Furthermore, patients treated with an
IVI of aflibercept had a significantly higher 72 h post-IVI
LFP flare than those injected with bevacizumab without
any clinical consequences.
In order to establish a cut-off for LFP flare levels that
should raise suspicion and justify a more thorough investi-
gation, we evaluated the distribution of post-IVI LFP flare.
Fig. 5 Patient 2. Pre-injection OCT showing intraretinal fluid due to diabetic macular edema
Fig. 6 Patient 2. Laser flare photometry values evolution from pre-injection values until the last follow-up
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In the two cases with flare > 50 ph/ms, there was a 3-day
time span between IVI and onset of endophthalmitis, in
concordance with previous reports [2, 7]. The clinical out-
come was exceptionally good due to early treatment.
These two cases confirm the importance of an evaluation
72-h post-IVI and show the sensitivity of using LFP to de-
tect the early signs of endophthalmitis, even when patients
are asymptomatic. Numerous reports in the literature in-
dicate that early treatment is associated with improved
visual outcomes, even with the most virulent agents [13,
14]. Follow-up with LFP also allowed verification that the
improvement in inflammation was steady and gradual.
In conclusion, we propose using LFP assessment per-
formed by an ophthalmic assistant to screen every pa-
tient 72-h post-intravitreal treatment, when such
screening cannot be performed by an ophthalmologist.
Flare values > 50 ph/ms should warrant immediate
evaluation by an ophthalmologist.
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